{"nctId":"NCT01443130","briefTitle":"Chloroquine for Malaria in Pregnancy","startDateStruct":{"date":"2012-02"},"conditions":["Malaria"],"count":900,"armGroups":[{"label":"Chloroquine IPT","type":"EXPERIMENTAL","interventionNames":["Drug: Chloroquine"]},{"label":"Chloroquine Prophylaxis","type":"EXPERIMENTAL","interventionNames":["Drug: Chloroquine"]},{"label":"SP IPT","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Sulfadoxine-pyrimethamine"]}],"interventions":[{"name":"Chloroquine","otherNames":[]},{"name":"Sulfadoxine-pyrimethamine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nWomen who present to the Ndirande Antenatal Clinic (ANC) and meet the following inclusion criteria will be enrolled in the study: -Before the end of 27th week of gestation -First or second pregnancy -Anticipate remaining in Blantyre until 14 weeks after delivery -Agree to deliver at the Ndirande Health Centre or Queen Elizabeth Central Hospital (QECH) -Provision of informed consent\n\nExclusion Criteria:\n\n-Chronic use (\\>14 days) of any medication with antimalarial or antifolate activity -Human immunodeficiency virus (HIV) infection -Known high-risk pregnancy requiring regular supervision of an obstetrician -Allergy to any of the study drugs","healthyVolunteers":false,"sex":"FEMALE","maximumAge":"99 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Placental Malaria Infection Based on Histology","description":"The placenta was collected at the time of delivery for examination by histology to determine malaria infection. Malaria infection was concluded if histology identified parasites or malaria pigment in the placental tissue.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.58","spread":null},{"groupId":"OG001","value":"15.42","spread":null},{"groupId":"OG002","value":"15.42","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Placental Malaria by Placental Impression Smear","description":"Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of malaria infection in the placenta based on diagnosis by positive placental impression smear results.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0.40","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Maternal Anemia (Hemoglobin < 10 Grams/Deciliter)","description":"Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of anemia among maternal participants during pregnancy . Anemia is defined as having a hemoglobin value less than 10 grams/deciliter (gm/dL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.3","spread":null},{"groupId":"OG001","value":"23.7","spread":null},{"groupId":"OG002","value":"22.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Maternal Severe Anemia (Hemoglobin < 7gm/dl)","description":"Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of severe anemia among maternal participants during pregnancy. Severe anemia is defined as having a hemoglobin value less than 7 gm/dl.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.3","spread":null},{"groupId":"OG002","value":"0.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Stillbirth","description":"Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was stillbirth, defined as an infant born without any signs of life at 28 weeks or greater of gestation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.10","spread":null},{"groupId":"OG001","value":"0.37","spread":null},{"groupId":"OG002","value":"1.90","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Miscarriage","description":"Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was miscarriage, defined as an infant delivered without any signs of life at less than 28 weeks of gestation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":null},{"groupId":"OG001","value":"0.67","spread":null},{"groupId":"OG002","value":"1.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Preterm Delivery","description":"Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was preterm delivery, defined as delivery less than 37 weeks of gestation. The outcome of the delivery was not considered, and could have been live birth, stillbirth, or miscarriage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.46","spread":null},{"groupId":"OG001","value":"9.89","spread":null},{"groupId":"OG002","value":"6.84","spread":null}]}]}]},{"type":"SECONDARY","title":"Infant Mortality Rate to 14 Weeks of Age","description":"Infants were followed from the time of delivery until 14 weeks of age. This outcome measure provides the incidence of infants who died within 14 weeks of delivery.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.22","spread":null},{"groupId":"OG001","value":"3.65","spread":null},{"groupId":"OG002","value":"3.09","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Low Birth Weight (LBW) (Birthweight < 2500 Grams)","description":"Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of infants whose birthweight was less than 2500 grams.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.59","spread":null},{"groupId":"OG001","value":"10.98","spread":null},{"groupId":"OG002","value":"12.11","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Intrauterine Growth Restriction (IUGR)","description":"Infants were followed from the time of delivery until 14 weeks of age. This outcome measure provides the incidence of infants with IUGR at delivery. IUGR is defined as weight below the 10th percentile for gestational age based on the World Health Organization (WHO) fetal growth curve. This classification is supported by literature resulting from the INTERGROWTH-21st Project; JosÃ© Villar.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.54","spread":null},{"groupId":"OG001","value":"18.01","spread":null},{"groupId":"OG002","value":"20.80","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Active Placental Malaria Infection","description":"Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of placental malaria infections in maternal subjects diagnosed by the presence of parasites and/or pigment on histological section or molecular evidence of infection (PCR).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.09","spread":null},{"groupId":"OG001","value":"3.16","spread":null},{"groupId":"OG002","value":"4.74","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Malaria Infection, All Species.","description":"Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of malaria infection episodes measured by positive parasitemia in maternal subjects.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":null},{"groupId":"OG001","value":"1.67","spread":null},{"groupId":"OG002","value":"3.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Clinical Malaria, All Species","description":"Maternal participants were followed to outcome of the pregnancy. Clinical malaria is defined as malaria infection at any parasite density with associated symptoms including at least one of the following: objective fever measured at the clinic, history of fever in the past 48 hours or other symptoms in the last 48 hours including: headache, myalgia, vomiting, or weakness.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":null},{"groupId":"OG001","value":"1.33","spread":null},{"groupId":"OG002","value":"3.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Infection in the Fetal Circulation","description":"Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of positive for malaria cord blood smear and cord PCR results in maternal subjects based on the results of the thick smear and PCR from the cord blood sample.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.95","spread":null},{"groupId":"OG001","value":"2.78","spread":null},{"groupId":"OG002","value":"0.80","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":23,"n":300},"commonTop":["Upper respiratory tract infection","Headache","Abdominal pain","Musculoskeletal pain","Vomiting"]}}}